(MedPage Today) — Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer’s disease, a secondary analysis of trial data showed. In phase II and III trials of… Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/114601 Author : Publish date : 2025-03-11 19:03:00 Copyright for syndicated content belongs to the linked […]
The post Brain Edema, Imaging Abnormalities Reported for Alzheimer’s Drug first appeared on News Health.
Author : News Health
Publish date : 2025-03-11 19:03:00
Copyright for syndicated content belongs to the linked Source.